ATE446751T1 - Verwendung von methylnaltrexon zur behandlung von immunsuppression - Google Patents
Verwendung von methylnaltrexon zur behandlung von immunsuppressionInfo
- Publication number
- ATE446751T1 ATE446751T1 AT02741899T AT02741899T ATE446751T1 AT E446751 T1 ATE446751 T1 AT E446751T1 AT 02741899 T AT02741899 T AT 02741899T AT 02741899 T AT02741899 T AT 02741899T AT E446751 T1 ATE446751 T1 AT E446751T1
- Authority
- AT
- Austria
- Prior art keywords
- methylnaltrexone
- opioid
- immunosupression
- treat
- methods
- Prior art date
Links
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 title abstract 2
- 229960002921 methylnaltrexone Drugs 0.000 title abstract 2
- 230000008629 immune suppression Effects 0.000 abstract 1
- 239000003887 narcotic antagonist Substances 0.000 abstract 1
- 239000003401 opiate antagonist Substances 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29557101P | 2001-06-05 | 2001-06-05 | |
| US37445402P | 2002-04-22 | 2002-04-22 | |
| PCT/US2002/018087 WO2002098422A1 (en) | 2001-06-05 | 2002-06-05 | Use of methylnaltrexone to treat immune suppression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE446751T1 true ATE446751T1 (de) | 2009-11-15 |
Family
ID=26969197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02741899T ATE446751T1 (de) | 2001-06-05 | 2002-06-05 | Verwendung von methylnaltrexon zur behandlung von immunsuppression |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030022909A1 (de) |
| EP (1) | EP1404323B1 (de) |
| JP (2) | JP2004535419A (de) |
| AT (1) | ATE446751T1 (de) |
| AU (1) | AU2002314967B2 (de) |
| CA (1) | CA2449175A1 (de) |
| DE (1) | DE60234183D1 (de) |
| WO (1) | WO2002098422A1 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
| US6274591B1 (en) * | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
| US20030130171A1 (en) * | 2001-10-30 | 2003-07-10 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant microbial cells |
| AU2013203378B2 (en) * | 2003-04-08 | 2016-09-15 | Progenics Pharmaceuticals, Inc. | Pharmaceutical formulations containing methylnaltrexone |
| US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| ES2528669T3 (es) * | 2003-04-08 | 2015-02-11 | Progenics Pharmaceuticals, Inc. | Formulaciones farmacéuticas que contienen metilnaltrexona |
| BRPI0409128A (pt) * | 2003-04-08 | 2006-03-28 | Progenics Pharm Inc | uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável |
| CA2521420A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
| BRPI0606587A2 (pt) * | 2005-01-20 | 2009-07-07 | Progenics Pharmaceuticais Inc | uso de metilnaltrexona e compostos correlatos para tratar disfunção gastrintestinal pós-operatória |
| EP1702558A1 (de) * | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Verfahren und Vorrichtung zur Darmtätigkeitserfassung |
| WO2006096626A2 (en) | 2005-03-07 | 2006-09-14 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| US20080287384A1 (en) * | 2005-09-19 | 2008-11-20 | Marsha Rosner | Methods of Identifying Agents Having Antiangiogenic Activity |
| KR101453107B1 (ko) | 2006-04-21 | 2014-10-27 | 디에스엠 아이피 어셋츠 비.브이. | 오피오이드 수용체 길항제의 용도 |
| US20070259939A1 (en) * | 2006-05-04 | 2007-11-08 | Accelerated Technologies | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
| JP2010510328A (ja) * | 2006-11-22 | 2010-04-02 | プロジェニックス ファーマスーティカルス インコーポレーテッド | ７，８−飽和−４，５−エポキシ−モルフィナニウム類似体の（ｒ）−ｎ−立体異性体 |
| PE20090700A1 (es) * | 2007-03-29 | 2009-07-13 | Progenics Pharm Inc | Compuestos heterociclicos como antagonistas del receptor opioide periferico |
| BRPI0809579B8 (pt) | 2007-03-29 | 2021-05-25 | Progenics Pharm Inc | formas cristalinas e seus usos |
| PL2139890T3 (pl) | 2007-03-29 | 2014-11-28 | Wyeth Llc | Antagoniści obwodowych receptorów opioidowych i ich zastosowania |
| WO2009076195A1 (en) * | 2007-12-05 | 2009-06-18 | The University Of Chicago | Treatment of drug-induced nausea with opioid antagonists |
| WO2009099411A1 (en) | 2008-02-06 | 2009-08-13 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
| AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| AU2009265034B2 (en) | 2008-07-01 | 2015-09-03 | University Of Chicago | Particles containing an opioid receptor antagonist and methods of use |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| KR101913102B1 (ko) | 2010-03-11 | 2018-10-31 | 와이어쓰 엘엘씨 | 메틸날트렉손의 경구 제형 및 친유성 염 |
| US9918980B2 (en) | 2011-04-29 | 2018-03-20 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
| US10736889B2 (en) | 2011-04-29 | 2020-08-11 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
| US10485798B2 (en) | 2012-08-22 | 2019-11-26 | Aptapharma Inc. | Methylnaltrexone nasal formulations, methods of making, and use thereof |
| WO2019227053A1 (en) * | 2018-05-25 | 2019-11-28 | Adamis Pharmaceuticals Corporation | Drug compositions |
| MX2022008554A (es) | 2020-01-10 | 2022-08-10 | Trevi Therapeutics Inc | Metodos de administracion de nalbufina. |
| US20220125844A1 (en) * | 2020-10-23 | 2022-04-28 | The Johns Hopkins University | Opioid antagonists for use in patients using chimeric antigen receptor t and natural killer (nk) cell therapy |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4176186A (en) * | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
| JPS5535031A (en) * | 1978-09-04 | 1980-03-11 | Shin Etsu Chem Co Ltd | Enteric coating composition |
| US4311833A (en) * | 1979-03-06 | 1982-01-19 | Daicel Chemical Industries Ltd. | Process for preparing ethylcarboxymethylcellulose |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4377568A (en) * | 1981-08-12 | 1983-03-22 | Merck Sharp & Dohme (I.A.) Corp. | Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same |
| DK150008C (da) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
| US4987136A (en) * | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
| US4457907A (en) * | 1982-08-05 | 1984-07-03 | Clear Lake Development Group | Composition and method for protecting a therapeutic drug |
| US4518433A (en) * | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4462839A (en) * | 1983-06-16 | 1984-07-31 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
| US4556552A (en) * | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
| DE3474511D1 (en) * | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| JPS6229515A (ja) * | 1985-07-30 | 1987-02-07 | Shinjiro Tsuji | 硬カプセル剤のフイルムコ−テイング方法 |
| US4861781A (en) * | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| US4719215A (en) | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| AU604052B2 (en) * | 1986-08-28 | 1990-12-06 | Enzacor Properties Limited | Animal growth promotant |
| US5597564A (en) * | 1986-08-28 | 1997-01-28 | Enzacor Properties Limited | Method of administering a microgranular preparation to the intestinal region of animals |
| US4888346A (en) * | 1986-10-07 | 1989-12-19 | Bernard Bihari | Method for the treatment of persons infected with HTLV-III (AIDS) virus |
| US4857833A (en) * | 1987-08-27 | 1989-08-15 | Teradyne, Inc. | Diagnosis of faults on circuit board |
| US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5270328A (en) * | 1991-03-29 | 1993-12-14 | Eli Lilly And Company | Peripherally selective piperidine opioid antagonists |
| JPH06508371A (ja) * | 1991-06-21 | 1994-09-22 | ユニバーシティー オブ シンシナティ | 経口投与できる治療用タンパク質及びその製法 |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
| US6096756A (en) * | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| US5472943A (en) * | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
| US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
| US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| DE69305313T3 (de) * | 1992-12-22 | 2001-06-21 | The University Of Cincinnati, Cincinnati | Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen |
| US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
| US5434171A (en) * | 1993-12-08 | 1995-07-18 | Eli Lilly And Company | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
| IT1269826B (it) * | 1994-05-24 | 1997-04-15 | Paolo Minoia | Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate |
| US5536507A (en) * | 1994-06-24 | 1996-07-16 | Bristol-Myers Squibb Company | Colonic drug delivery system |
| US5614222A (en) * | 1994-10-25 | 1997-03-25 | Kaplan; Milton R. | Stable aqueous drug suspensions and methods for preparation thereof |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| US5578725A (en) * | 1995-01-30 | 1996-11-26 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
| ES2094694B1 (es) * | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
| US6025154A (en) * | 1995-06-06 | 2000-02-15 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor HDGNR10 |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| WO1997028449A1 (en) * | 1996-02-02 | 1997-08-07 | Biotrin Intellectual Properties Limited | Method of determining the hepatic status of an individual, including a liver transplant recipient |
| PT914097E (pt) * | 1996-03-12 | 2002-06-28 | Alza Corp | Composicao e forma de dosagem compreendendo antagonista de opioide |
| DE19651551C2 (de) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
| US6353004B1 (en) * | 1997-07-14 | 2002-03-05 | Adolor Coporation | Peripherally acting anti-pruritic opiates |
| US6559158B1 (en) * | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
| US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
| US6274591B1 (en) * | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
| EP2266564B1 (de) | 1997-12-22 | 2013-03-13 | Euro-Celtique S.A. | Peroral zu verabreichende Arzneiform enthaltend eine Kombination von einem opioid Agonisten und einem opioid Antagonisten |
| US6194382B1 (en) * | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
| CA2380524A1 (en) * | 1999-08-25 | 2001-03-01 | Barrett R. Cooper | Compositions and methods for treating opiate intolerance |
| US6451806B2 (en) * | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| WO2001037785A2 (en) * | 1999-11-29 | 2001-05-31 | Adolor Corporation | Novel methods and compositions involving opioids and antagonists thereof |
| US6469030B2 (en) * | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
-
2002
- 2002-06-05 US US10/163,482 patent/US20030022909A1/en not_active Abandoned
- 2002-06-05 EP EP02741899A patent/EP1404323B1/de not_active Expired - Lifetime
- 2002-06-05 DE DE60234183T patent/DE60234183D1/de not_active Expired - Fee Related
- 2002-06-05 CA CA002449175A patent/CA2449175A1/en not_active Abandoned
- 2002-06-05 WO PCT/US2002/018087 patent/WO2002098422A1/en not_active Ceased
- 2002-06-05 JP JP2003501461A patent/JP2004535419A/ja active Pending
- 2002-06-05 AU AU2002314967A patent/AU2002314967B2/en not_active Ceased
- 2002-06-05 AT AT02741899T patent/ATE446751T1/de not_active IP Right Cessation
-
2009
- 2009-01-13 JP JP2009005238A patent/JP2009102382A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1404323A4 (de) | 2006-10-11 |
| JP2009102382A (ja) | 2009-05-14 |
| DE60234183D1 (de) | 2009-12-10 |
| WO2002098422A1 (en) | 2002-12-12 |
| EP1404323B1 (de) | 2009-10-28 |
| AU2002314967B2 (en) | 2007-09-20 |
| US20030022909A1 (en) | 2003-01-30 |
| CA2449175A1 (en) | 2002-12-12 |
| HK1064614A1 (en) | 2005-02-04 |
| JP2004535419A (ja) | 2004-11-25 |
| EP1404323A1 (de) | 2004-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE446751T1 (de) | Verwendung von methylnaltrexon zur behandlung von immunsuppression | |
| MXPA05010819A (es) | Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable. | |
| DE602004005076D1 (de) | Coextrudierte sicherheits-dosierform mit einem wirkstoff und einem adversen mittel und herstellungsverfahren dafür | |
| WO2005107726A3 (en) | Method for the treatment of back pain | |
| IL267381A (en) | A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders | |
| DE69925024D1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
| CY1108201T1 (el) | Συσκευες διαδερματικης απελευθερωσης οπιοειδους που ειναι ανθεκτικες στην παραβιαση | |
| DE60039783D1 (de) | Lfa-1 antagonisten und tnf-alpha antagonisten zur | |
| DE69823520D1 (de) | Noribogain zur behandlung von schmerzen und drogenabhängigkeit | |
| ATE388707T1 (de) | Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen | |
| DE69833971D1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
| MXPA04005003A (es) | Antagonistas de endotelina en un metodo y composicion para potenciar un analgesico opiaceo. | |
| WO2005000211A3 (en) | Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes | |
| WO2004091540A3 (en) | Methods of treating pain and compositions for use therefor | |
| CY1109264T1 (el) | Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου | |
| ATE437653T1 (de) | Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika | |
| EA200800766A1 (ru) | Ингибиторы pi3k для лечения эндометриоза | |
| DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
| ATE291425T1 (de) | R-eliprodil zur behandlung von glaucoma | |
| WO2004011018A3 (en) | Methods of identifying selective beta-1-adrenergic receptor antagonists | |
| MXPA05011593A (es) | Composicion farmaceutica que comprende un inhibidor de catepsina s y un opioide. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |